Thus, although all patients with high-risk GIST were included in the SSG XVIII pivotal clinical trial, there is broad consensus nowadays from sarcoma expert oncologists to not offer systemic adjuvant therapy to patients whose tumors are classified as KIT and PDGFRA WT nor to PDGFRA D842V–mutant GIST.12-14 Taken together, the total amount of primary resistant patients can reach up to 15%-20% of all cases.5-9. This evidence concerns the gene PDGFRA and sarcoma.